Evidence map›Paper›PMID 41351003›Full record

Trial reportCardiovascular diabetology2025

Effects of finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomised placebo-controlled mechanistic trial (FIVE-STAR).

Atsushi Tanaka, Muthiah Vaduganathan, Takumi Imai, Yosuke Okada, Satomi Sonoda, Keiichi Torimoto, Satoru Suwa, Hiroki Teragawa, Motoaki Miyazono, Makoto Fukuda and 21 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05887817 (Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in Type 2 Diabetes and Chronic Kidney Disease), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05887817 phase4unknown statusnot on this map

Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in Type 2 Diabetes and Chronic Kidney Disease (FIVE-STAR)

TypeinterventionalSponsorSaga UniversityRan2023 to 2026Enrolled100ConditionsType 2 Diabetes, Chronic Kidney DiseasesArmsFinerenone, Placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Atsushi TanakaDepartment of Cardiovascular Medicine, Saga University, Saga, Japan. tanakaa2@cc.saga-u.ac.jp.
Muthiah VaduganathanDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Takumi ImaiClinical Research Division, Organization for Clinical Medicine Promotion, Tokyo, Japan.
Yosuke OkadaClinical Research Center, Hospital of the University of Occupational and Environmental Health, Kitakyushu, Japan.
Satomi SonodaFirst Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Keiichi TorimotoFirst Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Satoru SuwaDepartment of Cardiology, Juntendo University Shizuoka Hospital, Izunokuni, Japan.
Hiroki TeragawaDepartment of Cardiovascular Medicine, JR Hiroshima Hospital, Hiroshima, Japan.
Motoaki MiyazonoDepartment of Nephrology, Saga University, Saga, Japan.
Makoto FukudaDepartment of Nephrology, Saga University, Saga, Japan.
Keisuke YonezuDepartment of Cardiology and Clinical Examination, Faculty of Medicine, Oita University, Yufu, Japan.
Naohiko TakahashiDepartment of Cardiology and Clinical Examination, Faculty of Medicine, Oita University, Yufu, Japan.
Yuichi YoshidaDepartment of Endocrinology, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Metabolism, Yufu, Japan.
Kenichi TanakaWakamatsu Hospital of the University of Occupational and Environmental Health, Kitakyushu, Japan.
Michio ShimabukuroDepartment of Diabetes, Endocrinology, and Metabolism, Fukushima Medical University School of Medicine, Fukushima, Japan.
Yuki HottaDepartment of Diabetes, Endocrinology, and Metabolism, Fukushima Medical University School of Medicine, Fukushima, Japan.
Masao MoroiDivision of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan.
Hiroki NiikuraDivision of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan.
Keisuke KidaDepartment of Pharmacology, St. Marianna University School of Medicine, Kawasaki, Japan.
Kenichi YokotaDivision of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Daiju FukudaDepartment of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Kengo TanabeDivision of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan.
Yu HoriuchiDivision of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan.
Shigeru ToyodaDepartment of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Japan.
Isao TaguchiDepartment of Cardiology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan.
Hisako YoshidaDepartment of Medical Statistics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Toru MiyoshiDepartment of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan.
Masaomi NangakuDivision of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Hirotaka ShibataDepartment of Endocrinology, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Metabolism, Yufu, Japan.
Koichi NodeDepartment of Cardiovascular Medicine, Saga University, Saga, Japan. node@cc.saga-u.ac.jp.
FIVE-STAR Investigators

Funding

Bayer Yakuhin N/A
6 · The paper itself

Abstract

backgroundThe mechanisms underlying cardiorenal benefits of finerenone remain unclear. This mechanistic trial aimed to evaluate the effects of finerenone on vascular stiffness, as assessed using the cardio-ankle vascular index (CAVI), and cardiorenal biomarkers in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD).

methodsEligible patients with T2D and CKD (estimated glomerular filtration rate [eGFR], 25 to < 90 mL/min/1.73 m

resultsThis investigator-initiated, multicentre, prospective, two-arm parallel, placebo-controlled, double-blind, randomised clinical trial was conducted at 13 sites in Japan. Among 102 patients randomised, 101 (66.3% men; median age, 73 years; eGFR, 56.2 mL/min/1.73 m

conclusionsFinerenone did not affect changes in vascular stiffness but led to a significant and sustained reduction in albuminuria in patients with T2D and CKD. The clinical benefits of finerenone may result from lowering intraglomerular pressure rather than from its effect on vascular stiffness. REGISTRATION: ClinicalTrial.gov (NCT05887817) and Japan Registry of Clinical Trials (jRCTs021230011).

Indexed as

AlbuminuriaDiabetes Mellitus, Type 2Diabetic NephropathiesKidneyMineralocorticoid Receptor AntagonistsNaphthyridinesRenal Insufficiency, ChronicVascular StiffnessAgedBiomarkersCardio Ankle Vascular IndexCreatinineDouble-Blind MethodFemaleGlomerular Filtration RateHumansBiomarkersCreatininefinerenoneMineralocorticoid Receptor AntagonistsNaphthyridinesBiomarkerChronic kidney diseaseFinerenoneProteomicsType 2 diabetesVascular stiffness

Identifiers

PMID41351003
PMCPMC12681115

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.